The World Health Organization listed AstraZeneca and Oxford University’s COVID-19 vaccine for emergency use.
According to Tedros Adhanom Ghebreyesus, WHO Director-General, “We now have all the pieces in place for the rapid distribution of vaccines. But we still need to scale up production.”
The AstraZeneca-Oxford vaccine has been lauded as less expensive to manufacture than the Pfizer and Moderna shots. Studies show that the two-dose vaccine is more effective when the second dose is delayed by more than six weeks.
Research also showed that the AstraZeneca-Oxford vaccine shot may not only protect against symptoms but reduces transmission by up to 67%. The vaccine has still not yet been approved for emergency use in the United States.
“We continue to call for COVID-19 vaccine developers to submit their dossiers to WHO for review at the same time as they submit them to regulators in high-income countries,” Ghebreyesus said